

IN THE CLAIMS:

Please enter the following amended claims:

1. (currently amended) A cell that expresses recombinase Cre in the presence of recombinase FLP in a FLP-dependent manner;
2. (original) The cell according to claim 1 that expresses the adenovirus E1A gene.
3. (original) The cell according to claim 1 or 2 that derives from human fetus kidney-derived cell line 293 cells.
4. (previously amended) The cell according to claim 1 or 2 having, in the genome thereof, a promoter, a recognition sequence of recombinase FLP, a stuffer sequence, a recognition sequence of recombinase FLP, and the recombinase Cre gene sequence in this order from upstream.
5. (currently amended) The cell according to claim 4 wherein the promoter is a hybrid promoter (CAG promoter) comprising a cytomegalovirus enhancer, a chicken β -actin promoter, and a rabbit β -globin splicing acceptor and which is operatively linked to a rabbit β -globin poly(A) sequence of rabbit β -globin.
6. (previously amended) The cell according to claim 4 wherein the stuffer sequence comprises a nucleotide sequence that acts so as to suppress the expression of the Cre gene located downstream thereof.
7. (original) The cell according to claim 6 which comprises a poly(A) sequence, or a nucleotide sequence encoding the desired protein and a poly(A) sequence, as a nucleotide sequence that acts so as to suppress the expression of the Cre gene.

8. (original) The cell according to claim 7 wherein the desired protein is the product of a drug resistant gene.

9. (original) The cell according to claim 8 wherein the drug resistant gene is a neomycin resistant gene.

10. (previously amended) The cell according to claim 4 having a nuclear localization signal at the 5'-end or 3'-end of the recombinase Cre gene.

11. (previously amended) A method of expressing recombinase Cre by introducing recombinase FLP into the cell according to claim 4.

12. (original) The method according to claim 11 wherein the method of introducing recombinase FLP uses an adenovirus vector.

13-20. (canceled).

21. (previously added) The cell according to claim 3 having, in the genome thereof, a promoter, a recognition sequence of recombinase FLP, a stuffer sequence, a recognition sequence of recombinase FLP, and the recombinase Cre gene sequence in this order from upstream.

22. (currently amended) The cell according to claim 21 wherein the promoter is a hybrid promoter (CAG promoter) comprising a cytomegalovirus enhancer, a chicken β -actin promoter, and a rabbit β -globin splicing acceptor and which is operatively linked to a rabbit β -globin poly(A) sequence of rabbit β -globin.

23. (previously added) The cell according to claim 21 wherein the stuffer sequence comprises a nucleotide sequence that acts so as to suppress the expression of the Cre gene located downstream thereof.

24. (previously added) The cell according to claim 23 which comprises a poly(A) sequence, or a nucleotide sequence encoding the desired protein and a poly(A) sequence, as a nucleotide sequence that acts so as to suppress the expression of the Cre gene.

25. (previously added) The cell according to claim 24 wherein the desired protein is the product of a drug resistant gene.

26. (previously added) The cell according to claim 25 wherein the drug resistant gene is a neomycin resistant gene.

27. (previously added) The cell according to claim 21 having a nuclear localization signal at the 5'-end or 3'-end of the recombinase Cre gene.

B¹ 28. (previously added) The cell according to claim 5 wherein the stuffer sequence comprises a nucleotide sequence that acts so as to suppress the expression of the Cre gene located downstream thereof.

29. (previously added) The cell according to claim 28 which comprises a poly(A) sequence, or a nucleotide sequence encoding the desired protein and a poly(A) sequence, as a nucleotide sequence that acts so as to suppress the expression of the Cre gene.

30. (previously added) The cell according to claim 29 wherein the desired protein is the product of a drug resistant gene.

31. (previously added) The cell according to claim 30 wherein the drug resistant gene is a neomycin resistant gene.

32. (previously added) The cell according to claim 5 having a nuclear localization signal at the 5'-end or 3'-end of the recombinase Cre gene.

33. (previously added) The cell according to claim 6 having a nuclear localization signal at the 5'-end or 3'-end of the recombinase Cre gene.

34. (previously added) The cell according to claim 7 having a nuclear localization signal at the 5'-end or 3'-end of the recombinase Cre gene.

35. (previously added) The cell according to claim 8 having a nuclear localization signal at the 5'-end or 3'-end of the recombinase Cre gene.

36. (previously added) The cell according to claim 9 having a nuclear localization signal at the 5'-end or 3'-end of the recombinase Cre gene.

37. (previously added) A method of expressing recombinase Cre by introducing recombinase FLP into the cell according to claim 5.

B1 38. (previously added) A method of expressing recombinase Cre by introducing recombinase FLP into the cell according to claim 6.

39. (previously added) A method of expressing recombinase Cre by introducing recombinase FLP into the cell according to claim 7.

40. (previously added) A method of expressing recombinase Cre by introducing recombinase FLP into the cell according to claim 8.

41. (previously added) A method of expressing recombinase Cre by introducing recombinase FLP into the cell according to claim 9.

42. (previously added) A method of expressing recombinase Cre by introducing recombinase FLP into the cell according to claim 10.

43-44. (canceled).
